Investor Centre
Latest updates
Announcement
Watch video recording of Cyclopharm's 2023 Annual General Meeting presentation on 16 May 2023
News
Cyclopharm’s CEO, James McBrayer, to participate in Emerging Leaders Conference hosted by Macquarie Equities in Melbourne on 14 June 2023
Webinar
Watch CANM webinar featuring Technegas clinical advancements
Company insights
1986
Technegas® was introduced to the medical community in 1986
64 countries
Technegas® revenues are generated in over 64 countries via a combination of direct and distributor sales models
4.7 million
Over 4.7 million patient procedures have been delivered to date
Delivering on our key growth objectives
Grow
Grow Technegas Sales 2022 sales revenue was $22.88 million – an increase of 32%
Expand
Expand the Use of Technegas There are currently 6 Cyclopharm sponsored Beyond PE clinical trials
Leverage
Leverage core strengths to continue to accelerate our third-party distribution business
Develop
Identify, develop and commercialise complementary innovative technology
Key catalysts for the next 2 years
Past announcements
Stay informed with our announcements
Subscribe to email alerts service
Whether you are a shareholder or not, you can subscribe to receive all company announcements through our email alerts service.
To join email alerts, simply fill in your details using the form below and nominate which announcements you would like to receive.
Your privacy is important to us. If you no longer want to receive email alerts, use the unsubscribe link. If you are a shareholder and want to change your details or check your holdings, then use the share registry information on the contact us page.